Orca Bio Revenue and Competitors

Claim your profile

Location

#615

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Orca Bio's estimated annual revenue is currently $18.5M per year.(i)
  • Orca Bio's estimated revenue per employee is $201,000
  • Orca Bio's total funding is $192M.
  • Orca Bio's current valuation is $1B.

Employee Data

  • Orca Bio has 92 Employees.(i)
  • Orca Bio grew their employee count by 42% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.2M6N/AN/AN/A
#2
N/A122-3%$62.5MN/A
#3
$138.3M688-4%N/AN/A
#4
$75.4M375N/AN/AN/A
#5
$63.9M318-8%N/AN/A
#6
$29.1M145N/AN/AN/A
#7
$892.7M205888%$54.8MN/A
#8
$1M567%$37MN/A
#9
$26.7M133-1%$206.1MN/A
#10
$56.7M51-37%$60MN/A

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patientsᅢᄁ¬ツᆲ¬トᄁ diseased blood and immune system with a healthy one. Our manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling us to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Our talented team is driven by a passion for science and compassion for patients.

keywords:N/A

$192M

Total Funding

92

Number of Employees

$18.5M

Revenue (est)

42%

Employee Growth %

$1B

Valuation

N/A

Accelerator

Orca Bio News

2020-06-17 - Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy

Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders High precision cell therapies manufactured by Orca Bio have the potential to replace conventional bone marrow transplants a ...

2020-06-17 - Orca Bio raises $192M in Series D round for effort to replace bone marrow transplants

The funding round, which brings the total amount of money Orca has raised to nearly $300 million since it was launched in 2016, will be used to develop its pipeline of cell therapies and its manufacturing technology, which involves optimizing therapeutic mixtures of immune and stem cells by sort ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13M934%$57.2M
#2
$20.7M948%N/A
#3
$22.5M942%N/A
#4
$21.8M961%N/A
#5
$24M9858%N/A